Aluminum, parathyroid hormone, and osteomalacia.
Aluminum exposure in man is unavoidable. The occurrence of dialysis dementia, vitamin D-resistant osteomalacia, and hypochromic microcytic anemia in dialysis patients underscores the potential for aluminum toxicity. Although exposure via dialysate and hyperalimentation leads to significant tissue aluminum accumulation, the ubiquitous occurrence of aluminum and the severe pathology associated with large aluminum burdens suggest that smaller exposures via the gastrointestinal tract and lungs could represent an important, though largely unrecognized, public health problem. It is clear that some aluminum absorption occurs with the ingestion of small amounts of aluminum in the diet and medicines, and even greater aluminum absorption is seen in individuals consuming large amounts of aluminum present in antacids. Aluminum absorption is enhanced in the presence of elevated circulating parathyroid hormone. In addition, elevated PTH leads to the preferential deposition of aluminum in brain and bone. Consequently, PTH is likely to be involved in the pathogenesis of toxicities in those organs. PTH excess also seems to lead to the deposition of aluminum in the parathyroid gland. The in vitro demonstration that aluminum inhibits parathyroid hormone release is consistent with the findings of a euparathyroid state in dialysis patients with aluminum related vitamin D-resistant osteomalacia. Nevertheless, it seems likely that hyperparathyroidism is at least initially involved in the pathogenesis of aluminum neurotoxicity and osteomalacia; the increases in tissue aluminum stores are followed by suppression of parathyroid hormone release, which is required for the evolution of osteomalacia. Impaired renal function is not a prerequisite for increased tissue aluminum burdens, nor for aluminum-related organ toxicity. Consequently, it is likely that these diseases will be observed in populations other than those with chronic renal disease.
D000535:Aluminum / Q000378:metabolism / Q000506:poisoning*; D000747:Anemia, Hypochromic / Q000209:etiology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology; D003704:Dementia / Q000209:etiology; D004781:Environmental Exposure; D006801:Humans; D007408:Intestinal Absorption; D010018:Osteomalacia / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000378:metabolism*; D010289:Parenteral Nutrition, Total; D006435:Renal Dialysis / Q000009:adverse effects
D010281:Parathyroid Hormone; D000535:Aluminum